The IPOs of agrochemical manufacturer India Pesticides and healthcare group Krishna Institute Of Medical Sciences (KIMS) are expected to touch Dalal Street in the near future. After filing their draught papers in February, both India Pesticides and KIMS obtained approval from capital market regulator Securities and Exchange Board of India (SEBI) for their public offerings in April. So far this year, 16 companies have launched their initial public offerings (IPOs) and debuted on the stock market. The IPO pipeline is still solid, with companies like Zomato starting the process for their initial public offering. India Pesticides, an agrochemicals maker, plans to collect Rs 800 crore from the market through its IPO. According to the company's drought red herring prospectus (DRHP), the IPO will include a fresh issue worth Rs 100 crore and an offer for sale (OFS) by existing shareholders for the remaining Rs 700 crore. Anand Swarup Agarwal, the company's founder, wants to sell shares worth Rs 281.4 crore, while other investors will make up the rest of the OFS. The company may opt for a Rs 75 crore pre-IPO placement, which would be reduced from the fresh problem. “India Pesticides Limited is an R&D driven agrochemical manufacturer of Technicals with a growing Formulations business,” Axis Securities said in a note. India Pesticides is the sole Indian manufacturer and one of the top five producers of many Technicals, including Folpet and Thiocarbamate Herbicide, according to the brokerage. The net proceeds are expected to be used to finance the company's working capital requirements. The Krishna Institute of Medical Sciences (KIMS), a major corporate healthcare company operating in Andhra Pradesh and Telangana, has also received SEBI's notice. According to the company's DRHP, it plans a fresh issue worth Rs 200 crore and an offer for sale of up to 21,340,931 equity shares by promoters and other investors. Bhaskara Rao Bollineni, the KIMS promoter, intends to sell 7.75 lakh equity shares; Rajyasri Bollineni intends to sell 11.63 lakh equity shares; and BRMH intends to sell 3.87 lakh shares. An investor in the firm, General Atlantic, will sell 1.39 crore equity shares, reducing its 41 percent stake in the company. At the end of last year, KIMS provided multidisciplinary integrated healthcare facilities in Tier 1 and Tier 2 cities, operating 9 multi-specialty hospitals under the KIMS Hospitals brand, with a bed capacity of 3,064 beds, including over 2,500 operational beds.